List of Excipients in Branded Drug LUMAKRAS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Amgen Inc	LUMAKRAS	sotorasib	55513-488	CELLULOSE, MICROCRYSTALLINE	2038-05-21
Amgen Inc	LUMAKRAS	sotorasib	55513-488	CROSCARMELLOSE SODIUM	2038-05-21
Amgen Inc	LUMAKRAS	sotorasib	55513-488	LACTOSE MONOHYDRATE	2038-05-21
Amgen Inc	LUMAKRAS	sotorasib	55513-488	MAGNESIUM STEARATE	2038-05-21

Lumakras Excipient Strategy and Commercial Opportunities for Sotorasib

Last updated: August 16, 2026

Lumakras, Amgen’s sotorasib, is an oral KRAS G12C inhibitor supplied as immediate-release film-coated tablets in 120 mg and 240 mg strengths. Its excipient strategy is commercially relevant because sotorasib has pH-dependent solubility, clinically important interactions with acid-reducing agents, and a label-supported dispersion method for patients who cannot swallow tablets. The strongest opportunities are in excipient qualification, pH-management technologies, patient-friendly oral delivery, and generic formulation development rather than in conventional tablet compression alone.

What formulation does Lumakras use?

Lumakras is an immediate-release, film-coated tablet. The FDA-approved product is administered orally once daily, with or without food. Patients may disperse the tablets in non-carbonated, room-temperature water when swallowing intact tablets is difficult. The tablets should not be crushed or chewed because the label does not establish equivalent performance for those administration methods. [1]

The FDA label identifies the following inactive ingredients for the tablet core:

Formulation function	Excipient or material
Diluent and compression aid	Microcrystalline cellulose
Superdisintegrant	Crospovidone
Lubricant	Magnesium stearate
Glidant and moisture-control aid	Colloidal silicon dioxide
Wetting or surfactant component	Sodium lauryl sulfate
Film-coating components	Polyvinyl alcohol-based coating system, titanium dioxide, talc and associated coating materials

The precise excipient composition should be read from the current approved labeling and any applicable regulatory filing because manufacturers can use different grades, coating systems and processing conditions while maintaining the same dosage form. The commercial formulation objective is rapid tablet breakup and reliable drug exposure without increasing the pH-dependent absorption risk associated with sotorasib. [1]

Why does sotorasib create an excipient opportunity?

Sotorasib has formulation sensitivity that distinguishes it from a routine immediate-release oncology tablet. Acid-reducing agents can lower sotorasib exposure. The FDA label reports reduced exposure with proton-pump inhibitors, H2-receptor antagonists and locally acting antacids. The label recommends avoiding concomitant acid-reducing treatment where possible and provides specific administration separation or alternative instructions when avoidance is not possible. [1]

This creates a formulation-development problem:

1. The dosage form must release sotorasib consistently.
2. It must avoid unnecessary microenvironmental changes that could reduce dissolution.
3. It must preserve exposure under practical patient-use conditions.
4. It should disperse adequately in water without requiring a new liquid formulation.
5. It must remain manufacturable at commercial scale.

Excipient selection can influence wetting, disintegration, particle dispersion, dissolution rate and local pH. A generic or lifecycle formulation that improves dissolution robustness under variable gastric conditions could have commercial value, but it would require comparative pharmacokinetic and bioequivalence evidence.

What excipients are most relevant to Lumakras formulation development?

Surfactants and wetting agents

Sodium lauryl sulfate is present in the approved formulation and may improve wetting of a poorly water-soluble active pharmaceutical ingredient. Its concentration and grade require control because excessive surfactant can affect dissolution profiles, tablet mechanical properties and gastrointestinal tolerability.

Alternative wetting systems could include poloxamers, polysorbates or other pharmaceutically accepted surfactants. These materials would need to demonstrate comparable or superior dissolution without introducing extractables, impurity or stability problems.

Superdisintegrants

Crospovidone supports rapid tablet breakup. Other candidates, including croscarmellose sodium and sodium starch glycolate, could provide different swelling and wicking behavior. The selection would affect:

• Dispersion time
• Dissolution in biorelevant media
• Tablet hardness
• Friability
• Performance after storage
• Suspension behavior when the tablet is dispersed in water

Crospovidone is commercially attractive because it supports rapid disintegration without relying primarily on swelling. That characteristic may help a tablet disperse more uniformly for patients using the label-supported water-dispersion method.

Silica and flow-control excipients

Colloidal silicon dioxide can improve powder flow and reduce manufacturing variability. It may be especially useful when the formulation contains a relatively high drug load or when the active has poor flow characteristics. The primary commercial opportunity is process robustness rather than patent differentiation.

Alternative silica grades, including treated or high-surface-area grades, could improve blend uniformity. The tradeoff is potential impact on compactability, lubricant distribution and dissolution.

Binders and compression aids

Microcrystalline cellulose is a standard direct-compression excipient. Alternative cellulose grades, copovidone, povidone or spray-dried composite excipients could support lower-cost manufacturing or smaller tablets.

A formulation developer would need to balance:

• Drug loading
• Tablet size
• Compression force
• Disintegration
• Coating performance
• Stability under humidity
• Risk of segregation during high-speed production

Film-coating systems

The coating is unlikely to be the primary driver of sotorasib exposure, but it affects manufacturability, swallowability, appearance and moisture protection. Commercial opportunities include lower-cost aqueous coating systems, titanium-dioxide-free color systems, improved coating uniformity and thinner coatings that reduce tablet weight.

A replacement coating must preserve tablet identity and mechanical protection without delaying disintegration. It also must satisfy market-specific requirements concerning titanium dioxide, colorants and animal-derived processing aids.

What formulation patents protect Lumakras?

The principal intellectual-property protection for Lumakras is expected to center on sotorasib as a chemical entity, pharmaceutical compositions, and therapeutic uses rather than on the individual use of common excipients. Composition-of-matter and method-of-use claims generally create a more significant barrier than claims directed to microcrystalline cellulose, crospovidone or magnesium stearate.

An excipient supplier should distinguish among four protection layers:

Protection layer	Commercial effect
Sotorasib composition-of-matter patents	Blocks unauthorized manufacture of the active ingredient until expiry
Pharmaceutical-composition patents	May cover defined drug-excipient combinations, ratios or release properties
Method-of-use patents	May restrict treatment of KRAS G12C-positive cancers
Regulatory exclusivity	Can delay ANDA approval independently of patent expiry

The FDA approved Lumakras under NDA 214665 in May 2021. The product received new chemical entity exclusivity, which generally prevents FDA approval of an ANDA referencing the product for five years from approval, subject to statutory Paragraph IV filing rules. Sotorasib’s initial accelerated approval for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer was converted to traditional approval in December 2022 after confirmatory evidence. [1,2]

The Orange Book status should be assessed by product strength and listed patent code. A generic formulation may need to address active ingredient, method-of-use and formulation-related patent listings. An excipient change does not by itself avoid a listed patent if the patent claims the active ingredient, treatment method or broader pharmaceutical composition.

When does Lumakras lose exclusivity?

Lumakras’ key regulatory milestones are:

Milestone	Date or status
FDA accelerated approval	May 28, 2021
FDA traditional approval conversion	December 2022
New chemical entity exclusivity	Expected to run through May 2026, subject to statutory adjustments
Initial indication	KRAS G12C-mutated locally advanced or metastatic NSCLC after at least one prior systemic therapy
Dosage forms	120 mg and 240 mg tablets
Biosimilar pathway	Not applicable because sotorasib is a small molecule
Generic pathway	ANDA, subject to applicable patents, exclusivity and product-specific requirements

Patent protection may extend beyond regulatory exclusivity. Public patent databases and FDA Orange Book listings should be reviewed for the current listed patents, terminal disclaimers and any patent-term adjustment. The commercial timing for generic sotorasib is therefore determined by the later of relevant regulatory barriers and enforceable patent claims, not by NCE exclusivity alone.

What generic entry risks exist for Lumakras?

The generic risk profile is moderate to high after core exclusivity barriers expire because the product is an oral small molecule with a conventional tablet presentation. The principal risks are formulation and clinical rather than manufacturing complexity.

Likely generic development pathway

A generic applicant would likely pursue:

1. A 120 mg and 240 mg immediate-release tablet.
2. Comparative dissolution across multiple pH conditions.
3. Bioequivalence against the reference listed drug.
4. A Paragraph IV certification against relevant listed patents.
5. Labeling that preserves the acid-reducing-agent warnings and water-dispersion instructions.

The strongest formulation differentiation would involve dissolution performance, excipient substitution, tablet size, coating composition or manufacturing cost. A generic applicant cannot assume that a standard tablet process will reproduce the reference product’s exposure because sotorasib’s interaction with gastric pH can complicate in vitro-in vivo correlation.

Paragraph IV exposure

A Paragraph IV challenge could target:

• Chemical compound claims
• Pharmaceutical-composition claims
• Treatment claims for KRAS G12C-mutated cancer
• Patents covering dosage regimens or combinations
• Any listed formulation claims

The probability of litigation depends on the number and scope of listed patents, the remaining patent term and whether the generic applicant pursues a first-filer strategy. A successful first Paragraph IV applicant could obtain 180 days of generic exclusivity, subject to statutory forfeiture rules.

What commercial opportunities exist for excipient suppliers?

1. Qualified alternate sources

Amgen’s commercial supply chain requires consistent excipient quality, low extractables and stable global availability. Suppliers can compete by offering dual-source capability for:

• Microcrystalline cellulose
• Crospovidone
• Colloidal silicon dioxide
• Sodium lauryl sulfate
• Magnesium stearate
• Film-coating systems

The value proposition is supply continuity, validated equivalence and regulatory documentation. Excipient replacement can trigger comparability work even when the ingredient is pharmacopoeial grade.

2. pH-robust formulation platforms

A high-value opportunity is a formulation platform that improves sotorasib dissolution without depending on acid suppression. Candidate approaches include:

• Amorphous solid dispersions
• Lipid-based systems
• Surfactant-assisted dispersion
• Nanocrystalline drug products
• pH-modifying microenvironments
• Co-processed excipient systems

These approaches would require careful control of precipitation, supersaturation, food effects and storage stability. The product’s approved tablet form creates a high bar for a reformulation because a new platform could require additional clinical work.

3. Patient-friendly oral delivery

The label already permits dispersion of Lumakras tablets in water. This creates a commercial opening for a dedicated oral suspension, dispersible tablet or orally disintegrating tablet, particularly for patients with dysphagia or advanced cancer-related treatment burdens.

A new dosage form could improve:

• Administration time
• Dose flexibility
• Swallowability
• Home-use convenience
• Adherence

The main development risks are taste, dose uniformity, chemical stability in water and equivalence to the approved tablet. A formulation marketed as easier to administer would likely require a new regulatory filing rather than a simple excipient substitution.

4. Region-specific coating and excipient compliance

Global markets increasingly impose restrictions on titanium dioxide, colorants, allergens and animal-derived materials. Excipient suppliers can offer regionally compliant coating systems that preserve appearance and performance across the United States, Europe and Asia-Pacific markets.

5. Generic enabling technologies

Once generic development becomes commercially viable, suppliers can provide ready-to-use excipient blends optimized for direct compression. The most attractive products would reduce:

• Blend segregation
• Compression variability
• Dissolution variability
• Coating time
• Cleaning requirements
• Scale-up risk

A co-processed filler-disintegrant system could be more commercially defensible than selling an individual commodity excipient.

How does Lumakras compare with other oral targeted oncology products?

Lumakras differs from many oral kinase inhibitors because gastric pH management is a prominent labeling issue. The comparison affects both formulation and commercial strategy.

Product characteristic	Lumakras	Typical oral kinase inhibitor
Active ingredient type	Small-molecule KRAS G12C inhibitor	Small-molecule targeted agent
Dosage form	Immediate-release film-coated tablet	Tablet or capsule
Biosimilar risk	None	None
Generic risk	Primarily after patents and exclusivity	Similar, but varies by formulation
Acid-reducing interaction	Clinically important	Product-specific
Water dispersion in label	Supported	Not routinely supported
Excipient differentiation	Potentially valuable for dissolution and dispersion	Often focused on manufacturability and stability

The closest technical competitors are other small-molecule oncology products with poor aqueous solubility, pH-dependent dissolution or significant food and drug-interaction effects. In those products, excipient strategy can affect the timing and cost of generic entry.

What is the commercial outlook for Lumakras excipients?

Lumakras is commercially meaningful but does not create a biologics-style excipient market. Its active ingredient is a small molecule, the marketed dosage form is a conventional tablet, and the excipients are largely established pharmaceutical materials.

The highest-value opportunities are:

• Supply-chain qualification for the reference product
• Performance-grade excipients that improve dissolution reproducibility
• Low-risk film-coating replacements
• Dispersible or suspension dosage forms
• Generic-ready direct-compression systems
• Excipient packages that maintain performance across pH conditions

Commodity volume alone is unlikely to produce large strategic value. Suppliers with the strongest position will combine excipient supply with formulation development, analytical method support, regulatory documentation and scale-up services.

Key Takeaways

• Lumakras is an immediate-release sotorasib tablet in 120 mg and 240 mg strengths.
• Its formulation uses conventional excipients, including microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide and sodium lauryl sulfate.
• Sotorasib’s pH-dependent exposure and acid-reducing-agent interaction make wetting, dissolution and dispersion important formulation variables.
• The FDA label permits dispersion of tablets in non-carbonated room-temperature water, creating opportunities for dedicated patient-friendly dosage forms.
• Sotorasib has no biosimilar exposure because it is a small molecule. Generic competition is the relevant post-exclusivity risk.
• NCE exclusivity is expected to extend to approximately May 2026, while patent protection may continue beyond that date.
• The strongest excipient opportunities involve qualified alternate sourcing, pH-robust dissolution, film-coating compliance and generic formulation enablement.
• Common excipients alone are unlikely to provide durable exclusivity unless combined with composition, process or performance claims.

FAQs

Can Lumakras be reformulated as an oral liquid?

Yes, but a commercial oral liquid would require development of chemical stability, dose uniformity, preservative control, taste management and comparative exposure data. The existing label supports tablet dispersion in water, not an extemporaneous liquid product with extended storage.

Which excipient is most important for sotorasib dissolution?

Sodium lauryl sulfate is a key wetting component in the approved formulation, while crospovidone supports rapid disintegration. Their performance depends on grade, concentration, granulation history and tablet compression conditions.

Could a generic manufacturer use different excipients from Lumakras?

Yes. An ANDA applicant can generally use different inactive ingredients if the formulation meets applicable safety, quality, dissolution and bioequivalence requirements. A different excipient system does not eliminate active ingredient or method-of-use patent risk.

Does Lumakras have biosimilar competition?

No. Sotorasib is a chemically synthesized small molecule. Competition would proceed through the generic drug pathway rather than the biosimilar pathway.

Could a new sotorasib formulation receive separate market exclusivity?

Potentially. A clinically meaningful new dosage form, indication or delivery technology could qualify for separate patent protection and, depending on the regulatory filing, additional exclusivity. The scope would depend on the formulation’s clinical and regulatory status.

References

1. U.S. Food and Drug Administration. (2024). Lumakras (sotorasib) prescribing information. Amgen Inc.
2. U.S. Food and Drug Administration. (2022). FDA grants regular approval to sotorasib for metastatic non-small cell lung cancer.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Inactive ingredient database.
5. U.S. Pharmacopeia. (2024). USP-NF general chapters and excipient standards.